Development of a Potent and Isoform-Selective HDAC11 Inhibitor with Anti-Tumor Efficacy against Non-Small Cell Lung Cancer
- 15 October 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (21) , 25236-25255
Abstract
Targeting histone deacetylase 11 (HDAC11) represents a promising therapeutic strategy, yet developing selective inhibitors for solid tumors remains a formidable challenge. Herein, we describe the rational lead optimization of a novel series of indole-based hydroxamic acids. Guided by our previous lead PB94, a systematic, multiparameter optimization of the core, linker, and cap regions was conducted to specifically target HDAC11. This campaign yielded compound YP200, which incorporates a precisely positioned secondary amine linker and an adamantane surface-recognition cap. YP200 exhibited exceptional HDAC11 inhibitory potency (IC50 = 0.058 ± 0.01 μM) and good selectivity (>103-fold) over other HDACs. Furthermore, YP200 demonstrated good in vivo anti-tumor efficacy in a non-small cell lung cancer (NSCLC) patient-derived xenograft model. These findings validate YP200 as a promising HDAC11-targeted therapeutic candidate, significantly expanding the therapeutic arsenal for solid tumors.Keywords
Funding Information
- 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (137220092)
- Sichuan Province Science and Technology Support Program (2025ZNSFSC0657)
- Basic Scientific Research Funds for Central Universities (20826041H4046)
This publication has 43 references indexed in Scilit:
- HDAC11 displays neuropathological alterations and offers as a novel drug target for Alzheimer's diseaseAlzheimer's & Dementia, 2025
- Targeting Histone Deacetylase 11 with a Highly Selective Inhibitor for the Treatment of MASLDAdvanced Science, 2025
- Histone deacetylases and their inhibitors in inflammatory diseasesBiomedicine & Pharmacotherapy, 2024
- HDAC11: A novel target for improved cancer therapyBiomedicine & Pharmacotherapy, 2023
- HDAC11: a rising star in epigeneticsBiomedicine & Pharmacotherapy, 2020
- Lung Cancer 2020Clinics in Chest Medicine, 2020
- Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in OncologyDrug Safety, 2019
- Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11Bioorganic & Medicinal Chemistry Letters, 2018
- HDAC11 is a regulator of diverse immune functionsBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2018
- Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors—What Some May Have Forgotten or Would Rather Forget?ChemMedChem, 2015